Evaluating Trastuzumab Deruxtecans Real-World Safety and Effectiveness in Chinese Patients with Advanced HER2-Positive Gastric or Gastroesophageal Junction Cancer

What this Trial Is About

Researchers are evaluating the real-world effectiveness and safety of Trastuzumab deruxtecan T-DXd in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in China. This observational study aims to collect real-world data because, although T-DXds efficacy and safety have been confirmed in traditional trials, there is limited evidence among Chinese patients. Participants who have decided to start T-DXd treatment starting dose 6.4 mgkg intravenously every 3 weeks in routine clinical practice will be enrolled. No study drug is provided as part of the trial instead, the study observes patients receiving T-DXd based on their physicians clinical judgment. The study follows participants for up to approximately 2 years. During the study, researchers will track the time from starting T-DXd to treatment failure, next treatment, or discontinuation due to disease progression, adverse events, or death. They will also monitor treatment-related adverse events and special physician-reported events. Participants health information will be collected throughout the study period to assess safety and effectiveness in a real-world setting.

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China